{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:55:00Z","timestamp":1788540900978,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Commercialization, Inc."},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.schres.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T21:03:07Z","timestamp":1463259787000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia"],"prefix":"10.1016","volume":"174","author":[{"given":"John M.","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Skuban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2016.04.013_bb0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.013_bb0010","first-page":"CD006622","article-title":"Aripiprazole versus placebo for schizophrenia","volume":"8","author":"Belgamwar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.schres.2016.04.013_bb0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4088\/JCP.v68n0416","article-title":"Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia","volume":"68","author":"Brecher","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.013_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1192\/bjp.176.2.173","article-title":"Determinants of quality of life at first presentation with schizophrenia","volume":"176","author":"Browne","year":"2000","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.04.013_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.schres.2016.04.013_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach","volume":"27","author":"Citrome","year":"2013","journal-title":"CNS Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2016.04.013_bb0035","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2016.04.013_bb0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.013_bb9000","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2016.04.012","article-title":"Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, doubleblind, placebo-controlled studies","author":"Correll","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2016.04.013_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.schres.2016.04.013_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis","volume":"26","author":"De Hert","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2016.04.013_bb0055","series-title":"Hamilton Anxiety Scale","first-page":"193","article-title":"ECDEU assessment manual for psychopharmacology (revised)","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.schres.2016.04.013_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12888-014-0365-x","article-title":"Validity of subjective versus objective quality of life assessment in people with schizophrenia","volume":"14","author":"Hayhurst","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.04.013_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.04.013_bb0070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0269881109348157","article-title":"Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials","volume":"24","author":"Kane","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.04.013_bb0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2016.04.013_bb0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2016.04.013_bb0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine d(2) occupancy, clinical response, and side effects: a double-blind pet study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.013_bb0090","first-page":"CD006625","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.schres.2016.04.013_bb0095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1017\/S1461145713001417","article-title":"5-ht2a receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis","volume":"17","author":"Laoutidis","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9896","key":"10.1016\/j.schres.2016.04.013_bb0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2016.04.013_bb0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.schres.2016.04.013_bb0110","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 18","key":"10.1016\/j.schres.2016.04.013_bb0115","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2016.04.013_bb0120","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"Prim. Care Companion. J. Clin. Psychiatry."},{"issue":"12","key":"10.1016\/j.schres.2016.04.013_bb0125","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.04.013_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2016.04.013_bb0135","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.schres.2016.04.013_bb0140","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.v66n0407","article-title":"Olanzapine increases slow wave sleep and sleep continuity in ssri-resistant depressed patients","volume":"66","author":"Sharpley","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.04.013_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"12","key":"10.1016\/j.schres.2016.04.013_bb0150","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","article-title":"Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making","volume":"10","author":"Volavka","year":"2009","journal-title":"Expert. Opin. Pharmacother."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416301621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T18:34:34Z","timestamp":1668710074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416301621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0920996416301621"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.013","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}